数据链接：
官方服务：
资源简介：
Risk of AMI associated with the use of SYSADOA.
应用场景：
创建时间：
2021-07-12
相关数据集
A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis. A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra
NIAID Data Ecosystem100
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression
Alzheimer’s disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. Ho
NIAID Data Ecosystem40
Multivariate models * assessing the link between exposure to corticosteroids during the various time-windows and occurrence of severe infection.
*Adjusted for mucosal or internal bleeding at diagnosis, lung disease, kidney disease, cardiac disease, diabetes mellitus, exposure to rituximab in the six months before index date, to azathioprine, m
NIAID Data Ecosystem30
Prior and Concomitant Medications and Systemic Antimicrobials in Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants <750 Grams Birth Weight
Prior and Concomitant Medications and Systemic Antimicrobials Dataset Study Description This was a prospective, randomized, double-blind, multi-center, efficacy study comparing fluconazole prophylaxis
NIAID Data Ecosystem50
Local and Solicited Systemic Reactogenicity.
Local and Solicited Systemic Reactogenicity.
NIAID Data Ecosystem40
